At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 59 enrolled
Drug / intervention
Remdesivirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19
In Brief
A Phase 3 clinical trial evaluating Remdesivir for COVID-19. Completed, enrolled 59 participants across 32 sites in 4 countries.
Detailed Summary
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesItaly, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedJun 16, 2020
Enrollment StartJul 21, 2020
Primary CompletionFeb 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.0 years ago
Interventions
Remdesivirdrug
Administered as an intravenous infusion